These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23382200)

  • 1. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.
    Jiao B; Ren ZH; Liu P; Chen LJ; Shi JY; Dong Y; Ablain J; Shi L; Gao L; Hu JP; Ren RB; de Thé H; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3495-500. PubMed ID: 23382200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
    Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
    Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
    Jansen JH; Löwenberg B
    Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
    Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.
    Guidez F; Parks S; Wong H; Jovanovic JV; Mays A; Gilkes AF; Mills KI; Guillemin MC; Hobbs RM; Pandolfi PP; de Thé H; Solomon E; Grimwade D
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18694-9. PubMed ID: 18000064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
    Chen Y; Li S; Zhou C; Li C; Ru K; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang B; Wang M; Wang J
    Blood; 2014 Aug; 124(6):936-45. PubMed ID: 24782508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
    Dong S; Tweardy DJ
    Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.
    Dong S; Zhu J; Reid A; Strutt P; Guidez F; Zhong HJ; Wang ZY; Licht J; Waxman S; Chomienne C; Chen Z; Zelent A; Chen SJ
    Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3624-9. PubMed ID: 8622986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies.
    Petti MC; Fazi F; Gentile M; Diverio D; De Fabritiis P; De Propris MS; Fiorini R; Spiriti MA; Padula F; Pelicci PG; Nervi C; Lo Coco F
    Blood; 2002 Aug; 100(3):1065-7. PubMed ID: 12130525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
    Beez S; Demmer P; Puccetti E
    PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
    Rice KL; Hormaeche I; Doulatov S; Flatow JM; Grimwade D; Mills KI; Leiva M; Ablain J; Ambardekar C; McConnell MJ; Dick JE; Licht JD
    Blood; 2009 Dec; 114(27):5499-511. PubMed ID: 19855079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
    Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
    Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
    Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.